Skip to main content

Clinical Trials Using BET Bromodomain Inhibitor ZEN-3694

Review the clinical trials studying bet bromodomain inhibitor zen-3694 on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-17 of 17

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients with Advanced Solid Tumors, The ComBET Trial
Status: Active
Location: 32 locations
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Status: Active
Location: 22 locations
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Status: Active
Location: 13 locations
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab plus Encorafenib, for Colorectal Cancer
Status: Active
Location: 12 locations
ZEN003694 for the Treatment of Recurrent or Metastatic Squamous Cell Lung Cancer Patients with NSD3 Amplification
Status: Active
Location: 7 locations
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 years) with Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Status: Active
Location: 7 locations
Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) with NUT Carcinoma
Status: Active
Location: 5 locations
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients with Advanced Triple-Negative Breast Cancer
Status: Active
Location: 5 locations
Testing the Combination of ZEN003694 and Nivolumab with or without Ipilimumab in Solid Tumors
Status: Active
Location: 6 locations
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 3 locations
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
Status: Active
Location: 3 locations
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 2 locations
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients with Advanced/Metastatic or Unresectable Solid Tumors with RAS Alterations and Triple Negative Breast Cancer
Status: Active
Location: 4 locations
ZEN003694 Combined with Talazoparib for the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Testosterone and ZEN-3694 followed by Enzalutamide and ZEN-3694 for the Treatment of Asymptomatic Patients with Metastatic Castration-Resistant Prostate Cancer, The COSMYC Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
ZEN003694 and Niraparib for the Treatment of Patients with Metastatic or Recurrent Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov